Brian J.G. Pereira
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a objective signifier pharmaceutical institution focused connected the discovery, development, and commercialization of oral, tiny molecule protease inhibitors, contiguous announced that the Board of Directors has appointed existent subordinate Brian J.G. Pereira, M.D., arsenic Chairman, effectual immediately. In conjunction, existent Chairman Martin Edwards, M.D. has resigned from the Board successful a planned modulation concurrent with the Company’s yearly meeting.
“We are pleased that Brian has agreed to instrumentality the Chairman relation astatine this captious time,” said Andrew Crockett, Chief Executive Officer of KalVista. “Brian’s agelong acquisition successful late-stage cause improvement and commercialization volition beryllium peculiarly invaluable successful his caller relation arsenic KalVista continues to turn into a pre-commercial institution focused connected advancing sebetralstat arsenic the archetypal oral on-demand therapy for attraction of HAE attacks. We besides convey Martin, who was 1 of the founding investors successful KalVista, for his years of loyal work and relationship to the company, and we privation him good successful his aboriginal endeavors.”
Dr. Pereira has been a subordinate of the KalVista Board of Directors since 2019 and is presently President & CEO of Visterra, Inc., a subsidiary of Otsuka Pharmaceuticals focused connected biologics probe and objective improvement of therapies for patients with immune-mediated and different hard-to-treat diseases. Dr. Pereira antecedently served arsenic President & CEO of AMAG Pharmaceuticals wherever helium raised 4 financing rounds astatine expanding valuations and built the objective development, manufacturing, supply-chain and commercialized infrastructure for Feraheme. Prior to AMAG Pharmaceuticals, helium held elder roles astatine Tufts Medical Center, including President and CEO of a Tufts Medical Center Physician Organization and interim COO. He is an Adjunct Professor of Medicine astatine Tufts University School of Medicine and has authored implicit 200 published technological articles. Dr. Pereira received his aesculapian grade (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute and MBA from Kellogg School of Management astatine Northwestern University.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is simply a pharmaceutical institution focused connected the discovery, development, and commercialization of oral, tiny molecule protease inhibitors for diseases with important unmet need. KalVista has developed a proprietary portfolio of novel, tiny molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is processing sebetralstat arsenic an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT objective trial. In addition, KalVista’s oral Factor XIIa inhibitor programme represents a caller procreation of therapies that whitethorn further amended the attraction for radical surviving with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 objective trial.
For much accusation astir KalVista, delight visit www.kalvista.com.
English (US)